Summary
Alnylam Pharmaceuticals, Inc. (ALNY) has reported a change in its Board of Directors structure. Marsha H. Fanucci will be resigning from the Board effective September 29, 2023. This departure is explicitly stated as not being due to any disagreements regarding the company's operations, policies, or practices, which suggests a smooth transition. Following Ms. Fanucci's resignation, Peter N. Kellogg is set to assume the role of Chair of the Audit Committee. The Board has confirmed Mr. Kellogg's qualification as an "audit committee financial expert," a key designation for financial oversight. Concurrently, the size of the Board will be reduced from thirteen to twelve members. These changes, while administrative, are important for investors to note regarding board composition and audit committee leadership.
Key Highlights
- 1Marsha H. Fanucci resigns from Alnylam's Board of Directors, effective September 29, 2023.
- 2Ms. Fanucci's resignation is not a result of any disagreements with the Company.
- 3Peter N. Kellogg will assume the role of Chair of the Audit Committee.
- 4Mr. Kellogg has been determined to be an "audit committee financial expert."
- 5The size of the Board of Directors will be reduced from thirteen to twelve members.